- Samsung Biologics has achieved new ISO 37301:2021 certification and renewed ISO 27001:2022 and ISO 27017:2015 standards.
Samsung Biologics has been awarded the ISO 37301:2021 certification for Compliance Management Systems, recognising the company’s commitment to organisational governance and adherence to global regulatory standards. This new certification, presented by the British Standards Institution (BSI), underlines Samsung Biologics’ ongoing efforts to build operational excellence as a global contract development and manufacturing organisation (CDMO).
The company also renewed its certifications for ISO 27001:2022, the updated standard for Information Security Management, and ISO 27017:2015, covering security in cloud services. These certifications reflect Samsung Biologics’ continued dedication to maintaining robust data protection and security protocols, ensuring the highest standards of information management for clients and stakeholders.
“We’re pleased to obtain certification for compliance as it’s a recognition of our unwavering focus to meeting the highest standards to build deeper trust with our clients and strengthen business competitiveness,” said John Rim, CEO and President of Samsung Biologics. He added that the company remains committed to strengthening ethical management practices while upholding high levels of security and privacy.
Alongside these achievements, Samsung Biologics maintains certifications across other critical areas, including anti-bribery management, quality management, and business continuity management.
Overview of outsourcing trends 
